TY - JOUR
T1 - Reductions in Radiographic Progression in Early Rheumatoid Arthritis Over Twenty-Five Years:
T2 - Changing Contribution From Rheumatoid Factor in Two Multicenter UK Inception Cohorts
AU - Carpenter, Lewis
AU - Norton, Sam
AU - Nikiphorou, Elena
AU - Jayakumar, Keeranur
AU - McWilliams, Daniel F.
AU - Rennie, Kirsten L.
AU - Dixey, Josh
AU - Kiely, Patrick
AU - Walsh, David Andrew
AU - Young, Adam
AU - on behalf of the Early Rheumatoid Arthritis Study and the Early Rheumatoid Arthritis Network
N1 - This is the peer reviewed version of the following article: Lewis Carpenter, et al, ‘Reductions in Radiographic Progression in Early Rheumatoid Arthritis Over Twenty-Five Years: Changing Contribution From Rheumatoid Factor in Two Multicenter UK Inception Cohorts’, Arthritis Care & Research, Vol. 69 (12): 1809-1817, December 2017, which has been published in final form at https://doi.org/10.1002/acr.23217. Under embargo until 6 Nov 2018
This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
PY - 2017/11/28
Y1 - 2017/11/28
N2 - Objective: To assess the 5-year progression of erosions and joint space narrowing (JSN) and their associations with rheumatoid factor (RF) status in 2 large, multicenter, early rheumatoid arthritis cohorts, spanning 25 years. Methods: Radiographic joint damage was recorded using the Sharp/van der Heijde (SHS) method in the Early Rheumatoid Arthritis Study (ERAS), 1986–2001, and the Early Rheumatoid Arthritis Network (ERAN), 2002–2013. Mixed-effects negative binomial regression estimated changes in radiographic damage over 5 years, including erosions and JSN, separately. RF, along with age, sex, and baseline markers of disease activity were controlled for. Results: A total of 1,216 patients from ERAS and 446 from ERAN had radiographic data. Compared to ERAS, ERAN patients had a lower mean total SHS score at baseline (ERAN 6.2 versus ERAS 10.5; P < 0.001) and mean annual rate of change (ERAN 2.5 per year versus ERAS 6.9 per year; P < 0.001). Seventy-four percent of ERAS and 27% of ERAN patients progressed ≥5 units. Lower scores at baseline in ERAN were largely driven by reductions in JSN (ERAS 3.9 versus ERAN 1.2; P < 0.001), along with erosions (ERAS 1.9 versus ERAN 0.8; P < 0.001). RF was associated with greater progression in each cohort, but the absolute difference in mean annual rate of change for RF-positive patients was substantially higher for ERAS (RF positive 8.6 versus RF negative 5.1; P < 0.001), relative to ERAN (RF positive 2.0 versus RF negative 1.9; P = 0.855). Conclusion: Radiographic progression was shown to be significantly reduced between the 2 cohorts, and was associated with lower baseline damage and other factors, including changes in early disease-modifying antirheumatic drug use. The impact of RF status as a prognostic marker of clinically meaningful change in radiographic progression has markedly diminished in the context of more modern treatment.
AB - Objective: To assess the 5-year progression of erosions and joint space narrowing (JSN) and their associations with rheumatoid factor (RF) status in 2 large, multicenter, early rheumatoid arthritis cohorts, spanning 25 years. Methods: Radiographic joint damage was recorded using the Sharp/van der Heijde (SHS) method in the Early Rheumatoid Arthritis Study (ERAS), 1986–2001, and the Early Rheumatoid Arthritis Network (ERAN), 2002–2013. Mixed-effects negative binomial regression estimated changes in radiographic damage over 5 years, including erosions and JSN, separately. RF, along with age, sex, and baseline markers of disease activity were controlled for. Results: A total of 1,216 patients from ERAS and 446 from ERAN had radiographic data. Compared to ERAS, ERAN patients had a lower mean total SHS score at baseline (ERAN 6.2 versus ERAS 10.5; P < 0.001) and mean annual rate of change (ERAN 2.5 per year versus ERAS 6.9 per year; P < 0.001). Seventy-four percent of ERAS and 27% of ERAN patients progressed ≥5 units. Lower scores at baseline in ERAN were largely driven by reductions in JSN (ERAS 3.9 versus ERAN 1.2; P < 0.001), along with erosions (ERAS 1.9 versus ERAN 0.8; P < 0.001). RF was associated with greater progression in each cohort, but the absolute difference in mean annual rate of change for RF-positive patients was substantially higher for ERAS (RF positive 8.6 versus RF negative 5.1; P < 0.001), relative to ERAN (RF positive 2.0 versus RF negative 1.9; P = 0.855). Conclusion: Radiographic progression was shown to be significantly reduced between the 2 cohorts, and was associated with lower baseline damage and other factors, including changes in early disease-modifying antirheumatic drug use. The impact of RF status as a prognostic marker of clinically meaningful change in radiographic progression has markedly diminished in the context of more modern treatment.
UR - http://www.scopus.com/inward/record.url?scp=85032993985&partnerID=8YFLogxK
U2 - 10.1002/acr.23217
DO - 10.1002/acr.23217
M3 - Article
C2 - 28217885
AN - SCOPUS:85032993985
SN - 2151-464X
VL - 69
SP - 1809
EP - 1817
JO - Arthritis Care and Research
JF - Arthritis Care and Research
IS - 12
ER -